Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases
Elisabetta Di Liso(Istituti di Ricovero e Cura a Carattere Scientifico), Valentina Guarneri(Istituto Oncologico Veneto), Angelo Paolo Dei Tos(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), PierFranco Conte(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Marcello Mele(University of Pisa), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua)
Cited by 33
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k